Caribou Biosciences (CRBU) Stock Forecast & Price Target

Caribou Biosciences is favorably positioned because its chRDNA CRISPR platform offers differentiated specificity with lower off-target risk, while also avoiding some of the IP complexity of older gene-editing approaches and benefiting from Pfizer validation through a $25 million equity investment. Its allogeneic CAR-T pipeline targets validated antigens such as CD19 and BCMA, increasing the probability of clinical relevance, and its design features like PD1 knockout, HLA-E knock-in, and targeted gene insertion could improve T-cell persistence and durability versus competing programs. Financially, 1Q26 net loss was $0.26 per share with R&D of $20.6 million and SG&A of $8.1 million, and $118.6 million in cash, cash equivalents, and marketable securities supports a runway into 2H27 ahead of data expected in 2H25.

Caribou Biosciences is facing a severely negative fundamental inflection because it has halted all clinical development across its two allogeneic CAR-T programs, vispa-cel and CB-011, effectively removing its core value drivers. Management cited a challenging financing environment and lack of capital availability, and even after the decision the company only had $113.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which appears insufficient to support meaningful pipeline advancement. With strategic alternatives now under review, workforce and cost reductions expected to finish by 4Q26, and a downside case assuming 0% probability of success across NHL, MM, AML, and the platform, the outlook reflects very limited operating optionality and heightened liquidation or restructuring risk.